Cannabis Science orders multiple greenhouse structures for its 2nd pilot 33,000 sq. ft. drug development facility buildout in Douglas County, Nevada.
Cannabis Science, Inc., a U.S. company specializing in the development of cannabinoid-based medications, has started work on its second 33,000 sq. ft. pilot cannabinoid drug development and manufacturing facility in Douglas County, Nevada.
“We have every intention of making 2017 the breakout year for our great company,” said CEO Raymond C. Dabney. “To fast track our second pilot greenhouse and property build program, we ordered prefabricated and regular greenhouses. This second pilot property will house some of our grow operations and research and development activity.
“Our target is to begin growing a variety of prime strains in the first quarter of 2017. We need all the drug development capacity we can get, because we intend to ramp up our operations to meet the increased demand for cannabinoid medications across the country. This market is coming into full-bloom, and 2017 is the year we will be positioned to capitalize on this tremendous opportunity.”
The Douglas County, Nevada multi-phased project is the second pilot site and is currently in full buildout of greenhouses, water-well development, extraction points, and manufacturing. The grow operations at this site will support the extraction of cannabinoids for the development of key proprietary formulations. The site management team is in place, and the labor crew is being hired locally to create jobs and economic benefits to the community. This multi-phased facility is officially under construction.
“The first quarter of 2017 will be an exciting time for more new product releases and much larger distribution channels. We will utilize various medication delivery methods (such as pills, creams, extracts, inhalers, tinctures, and balms) based on the ailment and we will release our cannabinoid-based medications across the country. I can’t emphasis enough what an exciting and busy year 2017 looks to be,” Dabney stated.
Cannabis Science is mapping out strategic demographic analyses across the country for full circle operations in each area: Grow, Lab Extraction, Manufacturing and Dispensaries. Having R&D and full circle operations and facilities in one site will allow Cannabis Science to bring its product to market more rapidly than before, while trimming costs for acquisition, extraction, and medication manufacturing.
While the company will place high emphasis on producing its existing product lines to meet the demand of current distributors, Cannabis Science will continue and expand the work on developing new product lines, which will allow them to access new patients across the country.
With over 3,500 acres in its portfolio in California and Nevada and much more under negotiations for future drug development projects, the company has a unique opportunity to scale out this model very quickly across the Western United States. Once this pilot buildout project in Nevada is complete and functional, the company will work on expanding its operations across the country.
(Source: Marketwired)
Filed Under: Drug Discovery
